Skip to main content

BioAtla, Inc.

corporate_fare Company Profile

BioAtla, Inc.

BCAB·OTC·Life Sciences·CIK 0001826892

We are a clinical-stage biopharmaceutical company focused on developing a new class of highly specific and selective antibody-based treatments for solid tumor cancers. Our conditionally active biologics, or CABs, utilize our proprietary discoveries in tumor biology to target known tumor antigens that have previously been challenging to address. These CAB therapeutic candidates exploit the characteristic acidic pH of the tumor microenvironment, which differs from healthy tissue. We design our antibodies to selectively bind to targets on cancer cells under acidic pH conditions, but not on targets in normal tissues. Our strategy aims to achieve the necessary targeting and potency for cancer cell destruction while eliminating or significantly reducing on-target, off-tumor toxicity, a common challenge with existing cancer therapies. The enhanced selectivity of our CAB technology is intended to improve the benefit-risk ratio for patients and allows for desired drug levels as monotherapy or in multi-targeted or combination therapies. The combination of reversible binding with the selective, precision capability of our CAB technology enables both increased antibody potency and reduced toxicity. Our proprietary CAB technology has the potential to transform antibody-based cancer therapy. Our goal is to develop well-tolerated, novel cancer therapies that provide cures or extended survival to improve patients' quality of life. Our CAB technology's broad applicability allows us to develop various product candidate modalities, including monoclonal antibodies, antibody-drug conjugates (ADCs), T cell-engaging bispecific antibodies, and chimeric antigen receptor T cells (CAR-T cells).

BioAtla, Inc. (OTC:BCAB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for BCAB at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • BioAtla to Reconvene Reverse Stock Split Vote; CEO Granted Super-Voting Share to Ensure Approval
  • BioAtla Creates Super-Voting Share for CEO to Force Reverse Stock Split After Failed Shareholder Vote

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$59.61M
Diluted EPS
-$1.01
Op. Cash Flow
-$48.2M
Operating Income
-$59.3M
Cash & Equivalents
$7.12M
Debt / Equity
0.00×
Shares Outstanding
63.46M sh
Source: 10-K · filed 2026-03-31 · accession 0001193125-26-134499
$1.55 +20.16% today
52-week range · as of 2026-11-16 $1.07 – $3575
Market cap
$2.59M
Volume
3.8K (0.6× avg)
3-mo avg 6.7K
Live data · 2026-11-22 12:44 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed BCAB - Filings & News (Page 2)

BCAB
Jan 15, 2026, 1:25 PM EST
Filing Type: DEFA14A
Importance Score:
9
Price at Filing: $0.3169
Real-time Price: $1.55 info
Change: Reverse Stock Split info
Market Cap: $2.586M info
BCAB
Jan 12, 2026, 4:30 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.3625
Real-time Price: $1.55 info
Change: Reverse Stock Split info
Market Cap: $2.586M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets